SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 6.65 |
| Enterprise Value ($M) | 0.86 |
| Book Value ($M) | 3.94 |
| Book Value / Share | 0.27 |
| Price / Book | 1.69 |
| NCAV ($M) | 3.22 |
| NCAV / Share | 0.22 |
| Price / NCAV | 2.06 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.73 |
| Return on Assets (ROA) | -1.37 |
| Return on Equity (ROE) | -1.60 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.95 |
| Current Ratio | 1.95 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 6.62 |
| Assets | 7.34 |
| Liabilities | 3.39 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -15.37 |
| Net Income | -15.02 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -12.32 |
| Cash from Investing | 0.00 |
| Cash from Financing | 4.75 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | YA II PN, Ltd. | 9.99 | ||
| 13D/A | Meckler Jeffrey A | 6.90 | 10.76 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,859 | 36,528 | 10.56 | |
| 5,433 | 60,177 | 9.03 | |
| 324 | 25,190 | 1.29 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| IMNN – Imunon, Inc. | IMTX – Immatics N.V. |
| INAB – IN8bio, Inc. | INKT – MiNK Therapeutics, Inc. |
| INM – InMed Pharmaceuticals Inc. |
Financial data and stock pages provided by
Fintel.io